- 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
- 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
- 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
- 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
- 如果EPS衰退，要觀察同業是不是有一樣的狀況
- 要留意增資減資和公司債對股本及EPS的影響
| 加權平均股數 QoQ YoY | EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | 營收 QoQ YoY | 毛利率(%) QoQ YoY | 營業利益率 QoQ YoY | 稅後淨利率 QoQ YoY | 營業利益 QoQ YoY | 稅後淨利 QoQ YoY | 稅前淨利率(%) QoQ YoY | 稅後淨利率(%) QoQ YoY | 兩季平均(YOY)營收成長率(%) | 兩季平均(YOY)EPS成長率(%) | 兩季平均(YOY)本業EPS成長率(%) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 270 | -1.1 | 6.72 | -0.14 | -40.0 | -600.0 | -0.17 | -6.25 | -1600.0 | -0.31 | -82.35 | 41.51 | 1.39 | -5.44 | -12.03 | 54.43 | 38.04 | 10.9 | -32.79 | -16.82 | -1468.9 | -27.28 | -45.57 | -631.37 | -0.45 | -9.76 | -1400.0 | -0.38 | -35.71 | -533.33 | -27.28 | -45.57 | -631.37 | -27.28 | -45.57 | -631.37 | -11.66 | -53.34 | -10.27 |
| 24Q2 (19) | 273 | 7.91 | 7.91 | -0.10 | -66.67 | 47.37 | -0.16 | -14.29 | 33.33 | -0.17 | -183.33 | 66.67 | 1.47 | -17.88 | 41.35 | 39.43 | 3.46 | 21.32 | -28.07 | -35.6 | 55.19 | -18.74 | -109.15 | 59.16 | -0.41 | -10.81 | 36.92 | -0.28 | -75.0 | 41.67 | -18.74 | -109.15 | 59.16 | -18.74 | -109.15 | 59.16 | -2.29 | 4.16 | -27.14 |
| 24Q1 (18) | 253 | 0.0 | 0.0 | -0.06 | 75.0 | 81.25 | -0.14 | -40.0 | 46.15 | -0.06 | 92.21 | 81.25 | 1.79 | 13.29 | 148.61 | 38.11 | -12.75 | -39.1 | -20.70 | -23.58 | 79.12 | -8.96 | 76.48 | 92.04 | -0.37 | -42.31 | 47.89 | -0.16 | 73.33 | 80.25 | -8.96 | 76.48 | 92.04 | -8.96 | 76.48 | 92.04 | 6.64 | -512.50 | -470.00 |
| 23Q4 (17) | 253 | 0.0 | 0.4 | -0.24 | -1100.0 | -60.0 | -0.10 | -900.0 | -211.11 | -0.77 | -45.28 | 28.04 | 1.58 | 0.0 | -51.53 | 43.68 | -11.0 | 9.09 | -16.75 | -701.44 | -315.85 | -38.10 | -921.45 | -229.3 | -0.26 | -766.67 | -204.0 | -0.6 | -900.0 | -57.89 | -38.10 | -921.45 | -229.3 | -38.10 | -921.45 | -229.3 | 25.96 | -505.26 | -402.08 |
| 23Q3 (16) | 253 | 0.0 | 0.4 | -0.02 | 89.47 | 85.71 | -0.01 | 95.83 | 95.45 | -0.53 | -3.92 | 42.39 | 1.58 | 51.92 | 62.89 | 49.08 | 51.02 | 39.79 | -2.09 | 96.66 | 96.6 | -3.73 | 91.87 | 89.99 | -0.03 | 95.38 | 94.92 | -0.06 | 87.5 | 83.33 | -3.73 | 91.87 | 89.99 | -3.73 | 91.87 | 89.99 | 48.18 | 65.05 | 51.76 |
| 23Q2 (15) | 253 | 0.0 | 0.4 | -0.19 | 40.62 | 36.67 | -0.24 | 7.69 | -14.29 | -0.51 | -59.38 | 33.77 | 1.04 | 44.44 | 5.05 | 32.50 | -48.07 | -36.07 | -62.64 | 36.81 | -11.94 | -45.89 | 59.24 | 39.86 | -0.65 | 8.45 | -16.07 | -0.48 | 40.74 | 36.84 | -45.89 | 59.24 | 39.86 | -45.89 | 59.24 | 39.86 | -16.73 | -36.36 | -190.60 |
| 23Q1 (14) | 253 | 0.4 | 0.4 | -0.32 | -113.33 | 31.91 | -0.26 | -388.89 | 31.58 | -0.32 | 70.09 | 31.91 | 0.72 | -77.91 | 75.61 | 62.58 | 56.29 | 4157.14 | -99.13 | -1377.45 | 60.55 | -112.59 | -873.12 | 61.77 | -0.71 | -384.0 | 30.39 | -0.81 | -113.16 | 32.5 | -112.59 | -873.12 | 61.77 | -112.59 | -873.12 | 61.77 | 79.09 | -60.23 | -123.99 |
| 22Q4 (13) | 252 | 0.0 | 0.0 | -0.15 | -7.14 | 87.29 | 0.09 | 140.91 | 110.0 | -1.07 | -16.3 | 42.78 | 3.26 | 236.08 | 328.95 | 40.04 | 14.04 | 159.68 | 7.76 | 112.61 | 102.43 | -11.57 | 68.94 | 97.06 | 0.25 | 142.37 | 110.33 | -0.38 | -5.56 | 87.29 | -11.57 | 68.94 | 97.06 | -11.57 | 68.94 | 97.06 | 117.03 | 23.09 | 68.08 |
| 22Q3 (12) | 252 | 0.0 | 0.0 | -0.14 | 53.33 | 54.84 | -0.22 | -4.76 | 15.38 | -0.92 | -19.48 | -35.29 | 0.97 | -2.02 | 6.59 | 35.11 | -30.94 | -24.99 | -61.52 | -9.94 | 18.09 | -37.25 | 51.19 | 56.41 | -0.59 | -5.36 | 13.24 | -0.36 | 52.63 | 53.85 | -37.25 | 51.19 | 56.41 | -37.25 | 51.19 | 56.41 | 69.72 | 44.75 | 19.99 |
| 22Q2 (11) | 252 | 0.0 | 0.0 | -0.30 | 36.17 | 23.08 | -0.21 | 44.74 | 36.36 | -0.77 | -63.83 | -108.11 | 0.99 | 141.46 | -36.13 | 50.84 | 3358.5 | 27.29 | -55.96 | 77.73 | 3.32 | -76.31 | 74.09 | -19.31 | -0.56 | 45.1 | 37.78 | -0.76 | 36.67 | 23.23 | -76.31 | 74.09 | -19.31 | -76.31 | 74.09 | -19.31 | 47.71 | 48.17 | 51.26 |
| 22Q1 (10) | 252 | 0.0 | 0.0 | -0.47 | 60.17 | -2450.0 | -0.38 | 57.78 | -18.75 | -0.47 | 74.87 | -2450.0 | 0.41 | -46.05 | -54.95 | 1.47 | 102.19 | -95.56 | -251.31 | 21.3 | -167.15 | -294.47 | 25.22 | -5563.27 | -1.02 | 57.85 | -18.6 | -1.2 | 59.87 | -2500.0 | -294.47 | 25.22 | -5563.27 | -294.47 | 25.22 | -5563.27 | -31.27 | -110.24 | -94.19 |
| 21Q4 (9) | 252 | 0.0 | 0.0 | -1.18 | -280.65 | -227.78 | -0.90 | -246.15 | -109.3 | -1.87 | -175.0 | -156.16 | 0.76 | -16.48 | -50.0 | -67.09 | -243.32 | -262.48 | -319.34 | -325.16 | -316.62 | -393.77 | -360.77 | -553.34 | -2.42 | -255.88 | -106.84 | -2.99 | -283.33 | -225.0 | -393.77 | -360.77 | -553.34 | -393.77 | -360.77 | -553.34 | -28.88 | -130.07 | -112.47 |
| 21Q3 (8) | 252 | 0.0 | 0.0 | -0.31 | 20.51 | -72.22 | -0.26 | 21.21 | -23.81 | -0.68 | -83.78 | -88.89 | 0.91 | -41.29 | -40.13 | 46.81 | 17.2 | 29.06 | -75.11 | -29.77 | -98.49 | -85.46 | -33.61 | -178.92 | -0.68 | 24.44 | -19.3 | -0.78 | 21.21 | -65.96 | -85.46 | -33.61 | -178.92 | -85.46 | -33.61 | -178.92 | 14.52 | -1014.75 | 9.04 |
| 21Q2 (7) | 252 | 0.0 | -0.79 | -0.39 | -2050.0 | -425.0 | -0.33 | -3.13 | -3200.0 | -0.37 | -1950.0 | -105.56 | 1.55 | 70.33 | -13.41 | 39.94 | 20.66 | -3.92 | -57.88 | 38.47 | -4847.01 | -63.96 | -1286.64 | -476.46 | -0.9 | -4.65 | -4400.0 | -0.99 | -2080.0 | -430.0 | -63.96 | -1286.64 | -476.46 | -63.96 | -1286.64 | -476.46 | 15.10 | -972.22 | 11.22 |
| 21Q1 (6) | 252 | 0.0 | 0.0 | 0.02 | 105.56 | 106.67 | -0.32 | 25.58 | -300.0 | 0.02 | 102.74 | 106.67 | 0.91 | -40.13 | -61.92 | 33.10 | -19.84 | -38.54 | -94.07 | -22.73 | -616.3 | 5.39 | 108.94 | 117.1 | -0.86 | 26.5 | -295.45 | 0.05 | 105.43 | 106.67 | 5.39 | 108.94 | 117.1 | 5.39 | 108.94 | 117.1 | -20.07 | 2.78 | -39.59 |
| 20Q4 (5) | 252 | 0.0 | 0.0 | -0.36 | -100.0 | -12.5 | -0.43 | -104.76 | 0 | -0.73 | -102.78 | 68.26 | 1.52 | 0.0 | -27.27 | 41.29 | 13.84 | 6.55 | -76.65 | -102.56 | -23853.13 | -60.27 | -96.7 | -54.1 | -1.17 | -105.26 | -11600.0 | -0.92 | -95.74 | -12.2 | -60.27 | -96.7 | -54.1 | -60.27 | -96.7 | -54.1 | - | - | 0.00 |
| 20Q3 (4) | 252 | -0.79 | 0.0 | -0.18 | -250.0 | 0.0 | -0.21 | -2000.0 | 0.0 | -0.36 | -100.0 | 0.0 | 1.52 | -15.08 | 0.0 | 36.27 | -12.75 | 0.0 | -37.84 | -3134.19 | 0.0 | -30.64 | -280.34 | 0.0 | -0.57 | -2750.0 | 0.0 | -0.47 | -256.67 | 0.0 | -30.64 | -280.34 | 0.0 | -30.64 | -280.34 | 0.0 | - | - | 0.00 |
| 20Q2 (3) | 254 | 0.79 | 0.0 | 0.12 | 140.0 | 0.0 | -0.01 | -106.25 | 0.0 | -0.18 | 40.0 | 0.0 | 1.79 | -25.1 | 0.0 | 41.57 | -22.82 | 0.0 | -1.17 | -106.42 | 0.0 | 16.99 | 153.9 | 0.0 | -0.02 | -104.55 | 0.0 | 0.3 | 140.0 | 0.0 | 16.99 | 153.9 | 0.0 | 16.99 | 153.9 | 0.0 | - | - | 0.00 |
| 20Q1 (2) | 252 | 0.0 | 0.0 | -0.30 | 6.25 | 0.0 | 0.16 | 0 | 0.0 | -0.30 | 86.96 | 0.0 | 2.39 | 14.35 | 0.0 | 53.86 | 38.99 | 0.0 | 18.22 | 5793.75 | 0.0 | -31.52 | 19.41 | 0.0 | 0.44 | 4500.0 | 0.0 | -0.75 | 8.54 | 0.0 | -31.52 | 19.41 | 0.0 | -31.52 | 19.41 | 0.0 | - | - | 0.00 |
| 19Q4 (1) | 252 | 0.0 | 0.0 | -0.32 | 0.0 | 0.0 | -0.00 | 0.0 | 0.0 | -2.30 | 0.0 | 0.0 | 2.09 | 0.0 | 0.0 | 38.75 | 0.0 | 0.0 | -0.32 | 0.0 | 0.0 | -39.11 | 0.0 | 0.0 | -0.01 | 0.0 | 0.0 | -0.82 | 0.0 | 0.0 | -39.11 | 0.0 | 0.0 | -39.11 | 0.0 | 0.0 | - | - | 0.00 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 0.42 | -4.8 | -2.66 | 5.06 | 34.44 | 1.36 | N/A | . | ||
| 2024/9 | 0.44 | -12.77 | -29.25 | 4.64 | 39.22 | 1.39 | 8.15 | . | ||
| 2024/8 | 0.5 | 13.55 | 1.57 | 4.21 | 54.86 | 1.39 | 8.15 | . | ||
| 2024/7 | 0.44 | 0.72 | -3.64 | 3.7 | 66.75 | 1.34 | 8.42 | . | ||
| 2024/6 | 0.44 | -3.79 | 35.72 | 3.26 | 85.15 | 1.47 | 7.95 | . | ||
| 2024/5 | 0.46 | -20.1 | 51.19 | 2.82 | 96.3 | 1.78 | 6.55 | . | ||
| 2024/4 | 0.57 | -24.04 | 37.59 | 2.36 | 108.34 | 1.92 | 6.07 | . | ||
| 2024/3 | 0.75 | 26.09 | 232.42 | 1.79 | 149.34 | 1.79 | 6.78 | 因肌肉注射劑型美國FDA發出拒絕提交信函，本季重新評估未來預計銷售數量，故本月營收有包括部分合約負債調整認列。 | ||
| 2024/2 | 0.6 | 36.29 | 147.4 | 1.04 | 110.99 | 1.62 | 7.47 | . | ||
| 2024/1 | 0.44 | -25.46 | 75.74 | 0.44 | 75.74 | 1.59 | 7.63 | . | ||
| 2023/12 | 0.59 | 4.18 | -39.22 | 4.92 | -13.1 | 1.58 | 8.0 | - | ||
| 2023/11 | 0.56 | 31.55 | -57.28 | 4.33 | -7.71 | 1.61 | 7.84 | 因去年度與Thera EU 中止合約，相關合約負債轉列收入，導致去年度收入較高 | ||
| 2023/10 | 0.43 | -30.8 | -57.25 | 3.76 | 11.73 | 1.54 | 8.19 | 因去年度與Thera EU 中止合約，相關合約負債轉列收入，導致去年度收入較高 | ||
| 2023/9 | 0.62 | 25.21 | 60.86 | 3.34 | 41.02 | 1.58 | 8.54 | 本月營收包含CDMO...等業務 | ||
| 2023/8 | 0.5 | 7.72 | 65.53 | 2.72 | 37.15 | 1.28 | 10.52 | . | ||
| 2023/7 | 0.46 | 41.89 | 63.68 | 2.22 | 32.1 | 1.09 | 12.39 | . | ||
| 2023/6 | 0.32 | 7.16 | 18.27 | 1.76 | 25.76 | 1.04 | 12.95 | . | ||
| 2023/5 | 0.3 | -27.29 | -3.4 | 1.44 | 27.58 | 0.94 | 14.29 | - | ||
| 2023/4 | 0.42 | 83.5 | 2.5 | 1.13 | 39.52 | 0.88 | 15.27 | . | ||
| 2023/3 | 0.23 | -6.15 | 75.89 | 0.72 | 76.45 | 0.72 | 19.15 | . | ||
| 2023/2 | 0.24 | -3.18 | 68.2 | 0.49 | 76.72 | 1.46 | 9.42 | . | ||
| 2023/1 | 0.25 | -74.22 | 85.83 | 0.25 | 85.83 | 2.54 | 5.41 | . | ||
| 2022/12 | 0.97 | -26.77 | 419.55 | 5.66 | 36.88 | 3.29 | 4.2 | 差異主要原因係將部分帳列合約負債權利金調整轉列營業收入認列所致。 | ||
| 2022/11 | 1.32 | 31.65 | 526.47 | 4.69 | 18.82 | 2.71 | 5.1 | 差異主要原因係本月認列部分Theratechnology歐洲權利金 | ||
| 2022/10 | 1.0 | 160.39 | 177.92 | 3.37 | -9.83 | 1.69 | 8.18 | 差異主要原因係本月認列部分Theratechnology歐洲權利金 | ||
| 2022/9 | 0.39 | 28.85 | 37.55 | 2.37 | -29.93 | 0.97 | 15.52 | - | ||
| 2022/8 | 0.3 | 6.52 | -3.04 | 1.98 | -36.04 | 0.85 | 17.55 | . | ||
| 2022/7 | 0.28 | 2.52 | -12.83 | 1.68 | -39.69 | 0.87 | 17.27 | - | ||
| 2022/6 | 0.27 | -12.47 | -41.07 | 1.4 | -43.21 | 0.99 | 14.83 | . | ||
| 2022/5 | 0.31 | -22.84 | -39.55 | 1.13 | -43.71 | 0.85 | 17.36 | - | ||
| 2022/4 | 0.41 | 214.89 | -28.7 | 0.81 | -45.16 | 0.68 | 21.7 | . | ||
| 2022/3 | 0.13 | -10.25 | 46.73 | 0.41 | -55.43 | 0.41 | 37.03 | 本公司規畫預計111年4月起開始銷售三星生物SBL生產之存貨給Theratechnologies | ||
| 2022/2 | 0.14 | 6.95 | -65.11 | 0.28 | -66.31 | 0.46 | 32.45 | . | ||
| 2022/1 | 0.13 | -27.93 | -67.5 | 0.13 | -67.5 | 0.53 | 28.33 | 歐洲銷售因會計認列時點調整遞延至Theratech實際銷售時認列收入，故ㄧ月銷售Theratech的一批次Trogarzo 暫不認列 | ||
| 2021/12 | 0.19 | -11.71 | -53.83 | 4.13 | -42.77 | 0.76 | 15.4 | . | ||
| 2021/11 | 0.21 | -41.59 | -62.31 | 3.95 | -42.12 | 0.85 | 13.7 | . | ||
| 2021/10 | 0.36 | 28.88 | -36.7 | 3.74 | -40.31 | 0.95 | 12.29 | . | ||
| 2021/9 | 0.28 | -9.17 | 6855.83 | 3.38 | -40.67 | 0.91 | 12.67 | . | ||
| 2021/8 | 0.31 | -4.22 | -43.45 | 3.1 | -45.56 | 1.1 | 10.54 | . | ||
| 2021/7 | 0.32 | -30.68 | -66.36 | 2.79 | -45.78 | 1.31 | 8.85 | . | ||
| 2021/6 | 0.46 | -10.22 | 0.92 | 2.46 | -41.07 | 1.55 | 7.57 | - | ||
| 2021/5 | 0.52 | -8.99 | -18.9 | 2.0 | -46.27 | 1.17 | 10.0 | - | ||
| 2021/4 | 0.57 | 548.05 | -17.66 | 1.48 | -51.94 | 1.07 | 11.0 | . | ||
| 2021/3 | 0.09 | -78.66 | -92.62 | 0.91 | -61.84 | 0.91 | 13.72 | 請參閱110年4月7日重大訊息「三月營收公告補充說明」 | ||
| 2021/2 | 0.41 | -0.36 | 38.32 | 0.82 | -31.37 | 1.23 | 10.19 | - | ||
| 2021/1 | 0.41 | 2.38 | -54.3 | 0.41 | -54.3 | 1.38 | 9.1 | . | ||
| 2020/12 | 0.4 | -27.92 | 0.0 | 7.22 | 2.6 | 1.53 | 8.21 | . | ||
| 2020/11 | 0.56 | -1.92 | -43.36 | 6.82 | -3.12 | 1.13 | 11.1 | - | ||
| 2020/10 | 0.57 | 14064.5 | -47.95 | 6.26 | 3.44 | 1.12 | 11.24 | - | ||
| 2020/9 | 0.0 | -99.26 | -99.42 | 5.69 | 14.82 | 1.51 | 7.63 | 因疫情影響TH庫存調整未採購，營收屬Q3折讓調整，與去年度比較今年營收成長15%目標不變。季底匯率評價調減本月大部分合併營收。 | ||
| 2020/8 | 0.55 | -43.03 | -36.11 | 5.69 | 33.63 | 1.96 | 5.85 | 本月營收為出貨給Theratechnologies用於歐洲未來銷售使用，先以較低之約定價格出售，待確認實際銷售價格時再予以調整。 | ||
| 2020/7 | 0.96 | 108.01 | 69.86 | 5.14 | 51.15 | 2.06 | 5.59 | . | ||
| 2020/6 | 0.46 | -27.86 | -8.77 | 4.18 | 47.43 | 1.79 | 5.8 | Q2因疫情美國各地封城影響，新病患人數減少，TH庫存調整本月未下訂單，本月營收 46,069仟元屬Q1及Q2銷貨折讓與實際數差異調整。 | ||
| 2020/5 | 0.64 | -7.6 | 1.14 | 3.72 | 59.61 | 2.52 | 4.12 | . | ||
| 2020/4 | 0.69 | -41.92 | 65.75 | 3.08 | 81.32 | 2.18 | 4.76 | . | ||
| 2020/3 | 1.19 | 299.93 | 79.42 | 2.39 | 86.37 | 2.39 | 4.24 | . | ||
| 2020/2 | 0.3 | -67.08 | 29.01 | 1.2 | 93.82 | 1.2 | 8.45 | 本月份Theratechnologies尚在進行調整庫存並未下採購訂單，本月中裕銷貨收入為2019第四季暫估銷售折讓與實際數差異調整 | ||
| 2020/1 | 0.9 | 0.0 | 132.2 | 0.9 | 132.2 | 1.89 | 5.36 | . | ||
| 2019/12 | 0.0 | -100.0 | -100.0 | 7.04 | 192.11 | 0.0 | N/A | 本月無營收主要係Theratechnologies進行存貨調整，108/12無訂貨，將遞延至109年開始訂貨，細節請參閱12/19重大訊息說明 | ||
| 2019/11 | 0.99 | -9.86 | 153.42 | 7.04 | 244.89 | 0.0 | N/A | . |
| 加權平均股數 YoY | EPS YoY | 本業EPS YoY | 營收 YoY | 毛利率(%) YoY | 營業利益率 YoY | 稅後淨利率 YoY | 營業利益 YoY | 稅前淨利 YoY | 稅後淨利 YoY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 253 | 0.4 | -0.77 | 0 | -0.61 | 0 | 4.92 | -12.61 | 45.80 | 19.55 | -33.80 | 0 | -39.61 | 0 | -1.66 | 0 | -1.95 | 0 | -1.95 | 0 |
| 2022 (9) | 252 | 0.0 | -1.07 | 0 | -0.71 | 0 | 5.63 | 36.32 | 38.31 | 88.63 | -34.08 | 0 | -47.83 | 0 | -1.92 | 0 | -2.69 | 0 | -2.69 | 0 |
| 2021 (8) | 252 | 0.0 | -1.87 | 0 | -1.80 | 0 | 4.13 | -42.8 | 20.31 | -54.32 | -117.64 | 0 | -113.91 | 0 | -4.86 | 0 | -4.71 | 0 | -4.71 | 0 |
| 2020 (7) | 252 | 0.0 | -0.73 | 0 | -0.49 | 0 | 7.22 | 2.41 | 44.46 | 36.17 | -18.38 | 0 | -25.37 | 0 | -1.33 | 0 | -1.83 | 0 | -1.83 | 0 |
| 2019 (6) | 252 | 0.4 | -2.30 | 0 | -1.44 | 0 | 7.05 | 192.53 | 32.65 | 0 | -55.36 | 0 | -82.14 | 0 | -3.9 | 0 | -5.79 | 0 | -5.79 | 0 |
| 2018 (5) | 251 | 0.4 | -1.28 | 0 | -1.19 | 0 | 2.41 | 2912.5 | -8.24 | 0 | -133.08 | 0 | -133.47 | 0 | -3.21 | 0 | -3.22 | 0 | -3.22 | 0 |
| 2017 (4) | 250 | 0.81 | -2.10 | 0 | -2.02 | 0 | 0.08 | 300.0 | 100.00 | 0.0 | -6462.97 | 0 | -6218.04 | 0 | -5.45 | 0 | -5.25 | 0 | -5.25 | 0 |
| 2016 (3) | 248 | 13.76 | -1.14 | 0 | -1.16 | 0 | 0.02 | 0 | 100.00 | 0 | -15072.20 | 0 | -13582.00 | 0 | -3.13 | 0 | -2.82 | 0 | -2.82 | 0 |
| 2015 (2) | 218 | 1.87 | -2.16 | 0 | -1.82 | 0 | 0 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | -4.91 | 0 | -4.72 | 0 | -4.72 | 0 |
| 2014 (1) | 214 | 10.31 | -1.32 | 0 | -1.10 | 0 | 0 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | -2.96 | 0 | -2.79 | 0 | -2.82 | 0 |
